CommentLarge trials confirm immunogenicity of H1N1 vaccines
References (16)
- et al.
On the relationship between mean antibody level, seroprotection and clinical protection from influenza
Biologicals
(2009) - et al.
Pandemic H1N1 influenza lessons from the southern hemisphere
Euro Surveill
(2009) - et al.
Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial
Lancet
(2009) Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines
Guideline on influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context
- et al.
Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009–10 influenza season: a multicentre, randomised controlled trial
Lancet
(2009) - et al.
Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials
Lancet
(2009) - et al.
Response after one dose of a monovalent influenza A (H1N1) 2009 vaccine—preliminary report
N Engl J Med
(2009)
Cited by (21)
Pandemic influenza H1N1 2009 infection in Victoria, Australia: No evidence for harm or benefit following receipt of seasonal influenza vaccine in 2009
2011, VaccineCitation Excerpt :The conflicting findings from observational studies on the effectiveness of seasonal influenza vaccination against infection with pandemic influenza highlight general problems with the estimation of influenza vaccine effectiveness. While most vaccines are licensed based on results from randomised controlled trials, influenza vaccines are licensed annually based only on immunogenicity studies and immunogenicity may not correspond with protection [26]. It is therefore important to estimate VE post-marketing.
Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents
2011, VaccineCitation Excerpt :The recent influenza pandemia due to a new A/H1N1 virus caused a higher incidence of hospitalisations and deaths than those caused yearly by seasonal influenza viruses, particularly in children and young people [10]. A number of specific inactivated adjuvanted and non-adjuvanted vaccines were prepared against this virus, which contained different amounts of antigen but were all capable of generating adequate antibody responses in healthy subjects [11]. However, although HIV-infected patients were included among the subjects having the right to priority in receiving vaccine immunization [12,13], the decision was not supported by specific studies of the immunogenicity, safety and tolerability of the different vaccine preparations in such patients.
Head-to-head comparison of pandemic influenza vaccines
2011, The Lancet Infectious DiseasesImmunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major
2010, VaccineCitation Excerpt :The recent influenza pandemic caused a new A/H1N1 virus led to a higher incidence of hospitalisations and death than the annual rates associated with seasonal influenza viruses [7]. A number of specific vaccines against this virus can generate adequate antibody responses in healthy subjects [8], but there are no published data concerning their efficacy in spenectomised and non-splenectomised patients with chronic anemia. The aim of this study was to evaluate the immunogenicity, safety, and tolerability of the 2009 monovalent pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major.
Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test-negative, hospital-based, case-control study
2010, VaccineCitation Excerpt :Our results support the effectiveness of vaccination to minimise the consequences of the circulation of a new pandemic influenza virus. The vaccines studied were adjuvanted (MF59 or AS03), of low antigen content compared to traditional seasonal vaccines and were administered in a one-dose schedule [43,44]. It is possible to put forward the hypotheses of an earlier than expected protection after the administration of these pandemic vaccines, as an effect is observed 7 or more days after one dose administration compared to the two weeks or two doses assumed necessary for more traditional influenza vaccines protection to appear.